ReviewCellular and molecular life sciences : CMLS2013
Depression and treatment response: dynamic interplay of signaling pathways and altered neural processes.
Review in Cellular and molecular life sciences : CMLS, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 80 citations in OpenAlex.
- MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes.Nature communications · 2017Trial
- The Differential Involvement of α1-Adrenoceptor Subtypes in the Molecular Effects of Antidepressant Drugs.International journal of molecular sciences · 2025Article
- A Comprehensive Review on Anxiolytic Effect ofFood science & nutrition · 2025Review
- Ketamine - An Imperfect Wonder Drug?Biochemical pharmacology · 2024Review
- ER stress in mouse serotonin neurons triggers a depressive phenotype alleviated by ketamine targeting eIF2α signaling.iScience · 2024Article
- Impact of Stress on Brain Morphology: Insights into Structural Biomarkers of Stress-related Disorders.Current neuropharmacology · 2024Review
- Circadian Rhythms and Sleep Disorders Associated to Major Depressive Disorder: Pathophysiology and Therapeutic Opportunities.CNS & neurological disorders drug targets · 2024Review
- Chronic Inflammatory Pain Alters Expression of Limbic MAPK Phosphatases.Chronic pain & management · 2024Article
- Neurotrophin Crosstalk in the Etiology and Treatment of Neuropsychiatric and Neurodegenerative Disease.Frontiers in molecular neuroscience · 2022Review
- Brain derived neurotrophic factor deficiency exacerbates inflammation-induced anhedonia in mice.Psychoneuroendocrinology · 2021Article
- Lithium augmentation of ketamine increases insulin signaling and antidepressant-like active stress coping in a rodent model of treatment-resistant depression.Translational psychiatry · 2021Article
- Stress Diminishes BDNF-stimulated TrkB Signaling, TrkB-NMDA Receptor Linkage and Neuronal Activity in the Rat Brain.Neuroscience · 2021Article
- BDNF Impact on Biological Markers of Depression-Role of Physical Exercise and Training.International journal of environmental research and public health · 2021Review
- Hemodynamic Response to Three Types of Urban Spaces before and after Lockdown during the COVID-19 Pandemic.International journal of environmental research and public health · 2021Article
- Serotonin receptor 4 in the hippocampus modulates mood and anxiety.Molecular psychiatry · 2021Article
- Validating a functional near-infrared spectroscopy diagnostic paradigm for Major Depressive Disorder.Scientific reports · 2020Article
- Corticosterone as a Potential Confounding Factor in Delineating Mechanisms Underlying Ketamine's Rapid Antidepressant Actions.Frontiers in pharmacology · 2020Article
- Dietary Exposure to Excess Saturated Fat During Early Life Alters Hippocampal Gene Expression and Increases Risk for Behavioral Disorders in Adulthood.Frontiers in neuroscience · 2020Article
- New insights into the cellular activities of Fndc5/Irisin and its signaling pathways.Cell & bioscience · 2020Review
- Relationship between VEGF-related gene polymorphisms and brain morphology in treatment-naïve patients with first-episode major depressive disorder.European archives of psychiatry and clinical neuroscience · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Since the 1960s, when the first tricyclic and monoamine oxidase inhibitor antidepressant drugs were introduced, most of the ensuing agents were designed to target similar brain pathways that elevate serotonin and/or norepinephrine signaling. Fifty years later, the main goal of the current depression research is to develop faster-acting, more effective therapeutic agents with fewer side effects, as currently available antidepressants are plagued by delayed therapeutic onset and low response rates. Clinical and basic science research studies have made significant progress towards deciphering the pathophysiological events within the brain involved in development, maintenance, and treatment of major depressive disorder. Imaging and postmortem brain studies in depressed human subjects, in combination with animal behavioral models of depression, have identified a number of different cellular events, intracellular signaling pathways, proteins, and target genes that are modulated by stress and are potentially vital mediators of antidepressant action. In this review, we focus on several neural mechanisms, primarily within the hippocampus and prefrontal cortex, which have recently been implicated in depression and treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.